Finch Therapeutics Group, Inc.
Index- P/E- EPS (ttm)-2.24 Insider Own0.10% Shs Outstand47.73M Perf Week0.00%
Market Cap23.27M Forward P/E- EPS next Y-1.59 Insider Trans-13.77% Shs Float23.40M Perf Month4.14%
Income-106.70M PEG- EPS next Q-0.34 Inst Own21.00% Short Float / Ratio0.53% / 1.02 Perf Quarter-60.32%
Sales1.70M P/S13.69 EPS this Y-77.80% Inst Trans1.90% Short Interest0.12M Perf Half Y-79.25%
Book/sh2.53 P/B0.20 EPS next Y21.70% ROA-50.40% Target Price12.50 Perf Year-94.03%
Cash/sh1.87 P/C0.27 EPS next 5Y41.70% ROE-64.50% 52W Range0.30 - 9.22 Perf YTD4.17%
Dividend- P/FCF- EPS past 5Y- ROI-28.80% 52W High-94.58% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low66.61% ATR0.06
Employees189 Current Ratio6.60 Sales Q/Q-99.10% Oper. Margin- RSI (14)43.99 Volatility6.76% 10.75%
OptionableYes Debt/Eq0.12 EPS Q/Q-303.10% Profit Margin- Rel Volume1.88 Prev Close0.51
ShortableYes LT Debt/Eq0.12 EarningsNov 10 BMO Payout- Avg Volume122.20K Price0.50
Recom2.00 SMA20-1.25% SMA50-20.22% SMA200-71.47% Volume119,801 Change-2.15%
Aug-09-22Initiated H.C. Wainwright Buy $17
Apr-13-21Initiated Jefferies Buy $29
Apr-13-21Initiated Evercore ISI Outperform $34
Apr-13-21Initiated BofA Securities Buy $25
Jan-24-23 01:53PM
Nov-10-22 08:15AM
08:00AM Loading…
Nov-09-22 08:00AM
Oct-24-22 08:00AM
Sep-05-22 12:00PM
Sep-01-22 02:23PM
Aug-26-22 07:37AM
Aug-25-22 04:30PM
Aug-11-22 07:00AM
Aug-10-22 08:06AM
09:48AM Loading…
Jul-20-22 09:48AM
Jun-02-22 07:00AM
May-17-22 08:00AM
May-16-22 07:00AM
May-09-22 08:22AM
Apr-29-22 12:10PM
Apr-28-22 05:20PM
Apr-20-22 12:33PM
Apr-19-22 02:08PM
Mar-31-22 04:56PM
Mar-19-22 08:04AM
Mar-01-22 04:30PM
Feb-23-22 07:00AM
Feb-10-22 07:00AM
05:38PM Loading…
Jan-18-22 05:38PM
Jan-06-22 07:00AM
Jan-04-22 07:00AM
Dec-23-21 04:38AM
Dec-20-21 07:00AM
Dec-17-21 06:31AM
Nov-11-21 07:00AM
Nov-10-21 07:15AM
Nov-09-21 04:30PM
Oct-25-21 07:00AM
Oct-18-21 08:58AM
Oct-12-21 07:00AM
Oct-05-21 07:00AM
Sep-08-21 07:00AM
Sep-07-21 07:00AM
Aug-18-21 08:54AM
Aug-10-21 03:54PM
Jun-28-21 07:00AM
May-28-21 07:00AM
May-13-21 07:00AM
May-06-21 07:00AM
Apr-27-21 07:00AM
Mar-19-21 04:25PM
Mar-18-21 10:32PM
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blaustein MarcChief Operating OfficerOct 21Sale1.393,6365,05432,614Oct 25 04:31 PM
Vittiglio JosephChief Business & Legal OfficerOct 21Sale1.393,6365,05431,364Oct 25 04:25 PM